Navigating the Efficacy and Safety of Oral Anticoagulation Use for Stroke Prevention in Very Elderly Patients With Atrial Fibrillation.
作者信息
Shin Seung Yong, Song Woo Hyuk, Lip Gregory Y H
机构信息
Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
School of Convergence and Innovation in Technology and Engineering, Pohang University of Science and Technology (POSTECH), Pohang, Korea.
出版信息
Korean Circ J. 2024 Dec;54(12):822-824. doi: 10.4070/kcj.2024.0309. Epub 2024 Oct 17.
Abstract
摘要
相似文献
1
Navigating the Efficacy and Safety of Oral Anticoagulation Use for Stroke Prevention in Very Elderly Patients With Atrial Fibrillation.探讨老年房颤患者口服抗凝药预防卒中的疗效与安全性。
Korean Circ J. 2024 Dec;54(12):822-824. doi: 10.4070/kcj.2024.0309. Epub 2024 Oct 17.
2
Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation and contraindication for anticoagulation.经皮左心耳封堵术用于房颤且有抗凝禁忌证患者的卒中预防
Rev Neurol (Paris). 2015 May;171(5):426-32. doi: 10.1016/j.neurol.2014.11.009. Epub 2015 Apr 23.
3
Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): statistical analysis plan for a randomised controlled trial.急性缺血性卒中合并心房颤动后抗凝治疗的最佳时机（OPTIMAS）：一项随机对照试验的统计分析计划
Trials. 2025 Feb 19;26(1):58. doi: 10.1186/s13063-025-08761-6.
4
[Interventional left atrial appendage occlusion : alternative to oral anticoagulation for stroke prevention in atrial fibrillation].[介入性左心耳封堵术：心房颤动患者预防卒中的口服抗凝替代方案]
Herz. 2013 May;38(3):239-46. doi: 10.1007/s00059-013-3775-5.
5
Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial.急性缺血性脑卒中合并心房颤动患者抗凝治疗的最佳时机（OPTIMAS）：一项随机对照试验方案。
Int J Stroke. 2022 Jun;17(5):583-589. doi: 10.1177/17474930211057722. Epub 2022 Jan 12.
6
Stroke prevention in elderly patients with atrial fibrillation.老年房颤患者的卒中预防
Singapore Med J. 2002 Apr;43(4):198-201.
7
Anticoagulation for stroke prevention in elderly patients with non-valvular atrial fibrillation: what are the obstacles?老年非瓣膜性心房颤动患者预防卒中的抗凝治疗：障碍有哪些？
Hong Kong Med J. 2016 Dec;22(6):608-15. doi: 10.12809/hkmj154803.
8
'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.“真实世界”的心房颤动抗栓治疗：EORP-AF 初步调查。
Am J Med. 2014 Jun;127(6):519-29.e1. doi: 10.1016/j.amjmed.2013.12.022. Epub 2014 Jan 28.
9
Navigating the choice of oral anticoagulation therapy for atrial fibrillation in the NOAC era.在新型口服抗凝药（NOAC）时代，为心房颤动患者选择口服抗凝治疗方案
Ther Adv Chronic Dis. 2017 Dec;8(12):165-176. doi: 10.1177/2040622317720106. Epub 2017 Jul 26.
10
[Reasons for underuse of oral anticoagulation in atrial fibrillation-associated stroke: prospective study of German stroke patients].[心房颤动相关性卒中患者口服抗凝药使用不足的原因：德国卒中患者的前瞻性研究]
Fortschr Neurol Psychiatr. 2008 Jul;76(7):391-5. doi: 10.1055/s-2008-1038216.
本文引用的文献
1
The Efficacy and Safety of NOAC in Very Elderly Atrial Fibrillation Patients: Data From the Korean National Health Insurance Cohort Registry.新型口服抗凝药在高龄房颤患者中的疗效与安全性：来自韩国国民健康保险队列登记处的数据
Korean Circ J. 2024 Dec;54(12):811-821. doi: 10.4070/kcj.2024.0073. Epub 2024 Jul 25.
2
2024 Chinese Expert Consensus Guidelines on the Diagnosis and Treatment of Atrial Fibrillation in the Elderly, Endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): Executive Summary.2024 年中国老年医学学会老年心血管病分会、中华医学会老年医学分会心血管病学组《老年心房颤动诊断与治疗中国专家共识（2024）》概要。
Thromb Haemost. 2024 Oct;124(10):897-911. doi: 10.1055/a-2325-5923. Epub 2024 May 14.
3
Racial Differences in Ischemic and Hemorrhagic Stroke: An Ecological Epidemiological Study.种族差异与缺血性卒中和出血性卒中：一项生态流行病学研究。
Thromb Haemost. 2024 Sep;124(9):883-892. doi: 10.1055/a-2278-8769. Epub 2024 Feb 29.
4
Racial Differences in Bleeding Risk: An Ecological Epidemiological Study Comparing Korea and United Kingdom Subjects.种族间出血风险的差异：一项比较韩国和英国人群的生态流行病学研究。
Thromb Haemost. 2024 Sep;124(9):842-851. doi: 10.1055/a-2269-1123. Epub 2024 Feb 15.
5
Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis.口服抗凝剂对合并多种药物治疗的心房颤动患者的影响：一项荟萃分析。
Thromb Haemost. 2025 Feb;125(2):166-177. doi: 10.1055/s-0043-1770724. Epub 2023 Jul 3.
6
The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.华法林与非维生素 K 拮抗剂口服抗凝剂在房颤患者中的有效性和安全性。
Thromb Haemost. 2024 Feb;124(2):135-148. doi: 10.1055/s-0043-1769735. Epub 2023 Jun 27.
7
Mobile Health-Technology-Integrated Care for Atrial Fibrillation: A Win Ratio Analysis from the mAFA-II Randomized Clinical Trial.移动医疗技术整合房颤治疗：mAFA-II 随机临床试验的赢率分析。
Thromb Haemost. 2023 Nov;123(11):1042-1048. doi: 10.1055/s-0043-1769612. Epub 2023 May 29.
8
Left Atrial Appendage Occlusion in the Elderly: Insights From PROTECT-AF, PREVAIL, and Continuous Access Registries.老年患者左心耳封堵术：来自 PROTECT-AF、PREVAIL 和连续入组登记研究的启示。
JACC Clin Electrophysiol. 2023 May;9(5):669-676. doi: 10.1016/j.jacep.2023.02.007. Epub 2023 Feb 27.
9
Clinical Complexity Domains, Anticoagulation, and Outcomes in Patients with Atrial Fibrillation: A Report from the GLORIA-AF Registry Phase II and III.心房颤动患者的临床复杂性领域、抗凝治疗与结局：GLORIA-AF 注册研究 II 期和 III 期报告。
Thromb Haemost. 2022 Dec;122(12):2030-2041. doi: 10.1055/s-0042-1756355. Epub 2022 Aug 29.
10
2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary.2021 年亚太心律学会心房颤动卒中预防聚焦更新共识指南：执行摘要。
Thromb Haemost. 2022 Jan;122(1):20-47. doi: 10.1055/s-0041-1739411. Epub 2021 Nov 13.
Zotero 插件